Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

The biology of incretin hormones

Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · see citing works

Glucagon-like peptide 1 (GLP-1)

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD

Mannino, D. M., Thorn, D. B., Swensen, A. R., & Holguín, F. (2008) · European Respiratory Journal · doi:10.1183/09031936.00012408 · Cited by 1,183 · see citing works

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works

Vitamin B12 deficiency

Green, R., Allen, L. H., Bjørke-Monsen, A.-L., Brito, A., Guéant, J.-L., Miller, J. W., Molloy, A. M., Nexo, E., Stabler, S., Toh, B.-H., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.40 · Cited by 970 · see citing works

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · see citing works

Chemotherapy-Induced Nausea and Vomiting

Hesketh, P. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706547 · Cited by 833 · see citing works

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial

Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790 · see citing works

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J. L., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 607 · see citing works

Understanding cachexia as a cancer metabolism syndrome

Porporato, P. E. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.3 · Cited by 562 · see citing works

Hindbrain Neurons as an Essential Hub in the Neuroanatomically Distributed Control of Energy Balance

Grill, H. J., & Hayes, M. R. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.015 · Cited by 483 · see citing works

Vitamin B12 deficiency.

Oh, R., & Brown, D. L. (2003) · PubMed · Cited by 468 · see citing works

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)

Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396 · see citing works

Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014

von Haehling, S., & Anker, S. D. (2014) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-014-0164-8 · Cited by 394 · see citing works

Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect

Sisley, S. R., Gutiérrez‐Aguilar, R., Scott, M. M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 394 · see citing works

A Recombinant Human Glucagon-Like Peptide (GLP)-1–Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor–Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis

Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 388 · see citing works

The Area Postrema and Vomiting

Miller, A. D., & Leslie, R. A. (1994) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1994.1012 · Cited by 375 · see citing works

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · see citing works

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond

Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365 · see citing works

Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4

Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · see citing works

Mechanisms of metabolic dysfunction in cancer-associated cachexiaPreprint

Petruzzelli, M., & Wagner, E. F. (2016) · Genes & Development · doi:10.1101/gad.276733.115 · Cited by 341 · see citing works

Beyond Comorbidity Counts: How Do Comorbidity Type and Severity Influence Diabetes Patients’ Treatment Priorities and Self-Management?

Kerr, E. A., Heisler, M., Krein, S. L., Kabeto, M., Langa, K. M., Weir, D., & Piette, J. D. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0313-2 · Cited by 330 · see citing works

Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016

von Haehling, S., Anker, M. S., & Anker, S. D. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12167 · Cited by 330 · see citing works

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326 · see citing works

Less aggressive treatment and worse overall survival in cancer patients with diabetes: A large population based analysis

van de Poll-Franse, L. V., Houterman, S., Janssen-Heijnen, M. L. G., Dercksen, M. W., Coebergh, J. W. W., & Haak, H. R. (2007) · International Journal of Cancer · doi:10.1002/ijc.22532 · Cited by 324 · see citing works

Fourth-Generation Epac-Based FRET Sensors for cAMP Feature Exceptional Brightness, Photostability and Dynamic Range: Characterization of Dedicated Sensors for FLIM, for Ratiometry and with High Affinity

Klarenbeek, J. B., Goedhart, J., van Batenburg, A. A., Groenewald, D., & Jalink, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122513 · Cited by 312 · see citing works

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305 · see citing works

GLP-1 and weight loss: unraveling the diverse neural circuitry

Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290 · see citing works

The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide

Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · see citing works

The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice

Chambers, A. P., Sorrell, J. E., Haller, A. M., Roelofs, K. J., Hutch, C. R., Kim, K., Gutiérrez‐Aguilar, R., Li, B., Drucker, D. J., D’Alessio, D. A., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.02.008 · Cited by 242 · see citing works

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

Rosenstock, J., Reusch, J. E. B., Bush, M., Yang, F., Stewart, M. W., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237 · see citing works

Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation

Hayes, M. R., Leichner, T. M., Zhao, S., Lee, G., Chowansky, A., Zimmer, D. J., Jonghe, B. C. D., Kanoski, S. E., Grill, H. J., & Bence, K. K. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.001 · Cited by 234 · see citing works

Reasons for Discontinuation of GLP1 Receptor Agonists: Data from a Real-World Cross-Sectional Survey of Physicians and Their Patients with Type 2 Diabetes

Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223 · see citing works

Prevalence of Overweight and Obesity Among Adults With Diagnosed Diabetes—United States, 1988-1994 and 1999-2002

(2005) · JAMA · doi:10.1001/jama.293.5.546 · Cited by 211 · see citing works

Why Can’t Rodents Vomit? A Comparative Behavioral, Anatomical, and Physiological Study

Horn, C. C., Kimball, B. A., Wang, H., Kaus, J., Dienel, S. J., Nagy, A., Gathright, G. R., Yates, B. J., & Andrews, P. L. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060537 · Cited by 210 · see citing works

Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts

Caughey, G. E., Roughead, E. E., Vitry, A. I., McDermott, R. A., Shakib, S., & Gilbert, A. L. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.019 · Cited by 201 · see citing works

Lean diabetes mellitus: An emerging entity in the era of obesity

George, A. M., Jacob, A. G., & Fogelfeld, L. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i4.613 · Cited by 177 · see citing works

The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors

Mietlicki‐Baase, E. G., Ortinski, P. I., Rupprecht, L. E., Olivos, D. R., Alhadeff, A. L., Pierce, R. C., & Hayes, M. R. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00413.2013 · Cited by 175 · see citing works

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM

Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174 · see citing works

Role of the glucagon-like-peptide-1 receptor in the control of energy balance

Hayes, M. R., De Jonghe, B. C., & Kanoski, S. E. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.02.029 · Cited by 173 · see citing works

Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice

Lamont, B. J., Li, Y., Kwan, E. P., Brown, T. J., Gaisano, H. Y., & Drucker, D. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42497 · Cited by 171 · see citing works

The Role of β Cell Glucagon-like Peptide-1 Signaling in Glucose Regulation and Response to Diabetes Drugs

Smith, E. P., An, Z., Wagner, C., Lewis, A. G., Cohen, E. B., Li, B., Mahbod, P., Sandoval, D. A., Pérez–Tilve, D., Tamarina, N. A., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.005 · Cited by 165 · see citing works

Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry

Echouffo-Tcheugui, J. B., Xu, H., DeVore, A. D., Schulte, P. J., Butler, J., Yancy, C. W., Bhatt, D. L., Hernandez, A. F., Heidenreich, P. A., & Fonarow, G. C. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.025 · Cited by 160 · see citing works

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13353 · Cited by 157 · see citing works

Suncus murinus: A new experimental model in emesis research

Ueno, S., Matsuki, N., & Saitō, H. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90229-3 · Cited by 154 · see citing works

Chronic Obstructive Pulmonary Disease and Diabetes Mellitus: A Systematic Review of the Literature

Gläser, S., Krüger, S., Merkel, M., Bramlage, P., & Herth, F. J. F. (2015) · Respiration · doi:10.1159/000369863 · Cited by 152 · see citing works

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

Drucker, D. J., Sherman, S. I., Bergenstal, R. M., & Buse, J. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0599 · Cited by 148 · see citing works

Effect of the cobalt‐N coordination on the cobamide recognition by the human vitamin B12 binding proteins intrinsic factor, transcobalamin and haptocorrin

Stupperich, E., & Nexø, E. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb16124.x · Cited by 143 · see citing works

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs

Simonsen, L., Holst, J. J., & Deacon, C. F. (2006) · Diabetologia · doi:10.1007/s00125-005-0128-9 · Cited by 133 · see citing works

GLP-1 Influences Food and Drug Reward

Hayes, M. R., & Schmidt, H. D. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.02.005 · Cited by 108 · see citing works

Diabetes and HIV

Nouno, E. C. N., Katte, J.-C. N., & Sobngwi, E. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1076-3 · Cited by 103 · see citing works

Endogenous glucagon-like peptide-1 receptor signaling in the nucleus tractus solitarius is required for food intake control

Alhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102 · see citing works

Investigation of Exenatide Elimination and Its In Vivo and In Vitro Degradation

Copley, K., McCowen, K. M., Hiles, R., Nielsen, L. L., Young, A. J., & Parkes, D. G. (2006) · Current Drug Metabolism · doi:10.2174/138920006776873490 · Cited by 100 · see citing works

Vitamin B12 as a carrier of peptide nucleic acid (PNA) into bacterial cells

Równicki, M., Wojciechowska, M., Wierzba, A. J., Czarnecki, J., Bartosik, D., Gryko, D., & Trylska, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-08032-8 · Cited by 91 · see citing works

Incretins and Amylin: Neuroendocrine Communication Between the Gut, Pancreas, and Brain in Control of Food Intake and Blood Glucose

Hayes, M. R., Mietlicki‐Baase, E. G., Kanoski, S. E., & Jonghe, B. C. D. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161201 · Cited by 90 · see citing works

Clinical profile of lean NIDDM in South India

Mohan, V., Vijayaprabha, R., Rema, M., Premalatha, G., Poongothai, S., Deepa, R., Bhatia, E., Mackay, I. R., & Zimmet, P. (1997) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(97)00088-0 · Cited by 80 · see citing works

Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes

Gallo, M., Muscogiuri, G., Felicetti, F., Faggiano, A., Trimarchi, F., Arvat, E., Vigneri, R., & Colao, A. (2017) · Metabolism · doi:10.1016/j.metabol.2017.09.013 · Cited by 70 · see citing works

Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus)

Jonghe, B. C. D., & Horn, C. C. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90952.2008 · Cited by 69 · see citing works

Lean versus obese diabetes mellitus patients in the United States minority population

Coleman, N. J., Miernik, J., Philipson, L., & Fogelfeld, L. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.11.010 · Cited by 59 · see citing works

CF‐related diabetes: Containing the metabolic miscreant of cystic fibrosis

Moheet, A. A., & Moran, A. (2017) · Pediatric Pulmonology · doi:10.1002/ppul.23762 · Cited by 54 · see citing works

Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors

Chepurny, O. G., Bonaccorso, R. L., Leech, C. A., Wöllert, T., Langford, G. M., Schwede, F., Roth, C. L., Doyle, R. P., & Holz, G. G. (2018) · Scientific Reports · doi:10.1038/s41598-018-22106-1 · Cited by 49 · see citing works

Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP

Chepurny, O. G., Matsoukas, M., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005682 · Cited by 41 · see citing works

Mouse Transcobalamin Has Features Resembling both Human Transcobalamin and Haptocorrin

Hygum, K., Lildballe, D. L., Greibe, E., Morkbak, A. L., Poulsen, S. S., Sørensen, B. S., Petersen, T. E., & Nexø, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020638 · Cited by 39 · see citing works

Measuring the nausea-to-emesis continuum in non-human animals: refocusing on gastrointestinal vagal signaling

Horn, C. C. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-3985-y · Cited by 38 · see citing works

Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries

Hartmann, B., Lanzinger, S., Bramlage, P., Groß, F., Danne, T., Wagner, S., Krakow, D., Zimmermann, A., Malcharzik, C., & Holl, R. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183235 · Cited by 38 · see citing works

Congestive Heart Failure and Diabetes Mellitus: Balancing Glycemic Control with Heart Failure Improvement

Nasir, S., & Aguilar, D. A. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.031 · Cited by 37 · see citing works

Glutamate Receptors in the Central Nucleus of the Amygdala Mediate Cisplatin-Induced Malaise and Energy Balance Dysregulation through Direct Hindbrain Projections

Alhadeff, A. L., Holland, R. A., Nelson, A., Grill, H. J., & Jonghe, B. C. D. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0440-15.2015 · Cited by 37 · see citing works

A vitamin B12 conjugate of exendin‐4 improves glucose tolerance without associated nausea or hypophagia in rodents

Mietlicki‐Baase, E. G., Liberini, C. G., Workinger, J. L., Bonaccorso, R. L., Borner, T., Reiner, D. J., Koch‐Laskowski, K., McGrath, L. E., Lhamo, R., Stein, L. M., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13222 · Cited by 36 · see citing works

Cobalamin-binding capacity of haptocorrin and transcobalamin: age-correlated reference intervals and values from patients.

Gimsing, P., & Nexø, E. (1989) · Clinical Chemistry · doi:10.1093/clinchem/35.7.1447 · Cited by 36 · see citing works

Noncobalamin vitamin B12 analogues in human red cells, liver, and brain

Kanazawa, S., & Herbert, V. D. (1983) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/37.5.774 · Cited by 36 · see citing works

Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in Suncus murinus (house musk shrew)

Chan, S. W., Lin, G., Yew, D. T. W., Yeung, C. K., & Rudd, J. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.01.013 · Cited by 34 · see citing works

Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment,

Chevalier, S., & Farsijani, S. (2013) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2013-0369 · Cited by 34 · see citing works

A New Principle for Measurement of Cobalamin and Corrinoids, Used for Studies of Cobalamin Analogs on Serum Haptocorrin

Hardlei, T. F., & Nexø, E. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.114132 · Cited by 30 · see citing works

Synthesis, Characterization and Pharmacodynamics of Vitamin‐B12‐Conjugated Glucagon‐Like Peptide‐1

Clardy‐James, S., Chepurny, O. G., Leech, C. A., Holz, G. G., & Doyle, R. P. (2012) · ChemMedChem · doi:10.1002/cmdc.201200461 · Cited by 28 · see citing works

89Zr-Cobalamin PET Tracer: Synthesis, Cellular Uptake, and Use for Tumor Imaging

Kuda‐Wedagedara, A. N. W., Workinger, J. L., Nexø, E., Doyle, R. P., & Viola, N. T. (2017) · ACS Omega · doi:10.1021/acsomega.7b01180 · Cited by 27 · see citing works

Induction of a Melanoma‐Specific Antibody Response by a Monovalent, but not a Divalent, Synthetic GM2 Neoglycopeptide

Bay, S., Fort, S., Birikaki, L., Ganneau, C., Samain, E., Coïc, Y., Bonhomme, F., Dériaud, E., Leclerc, C., & Lo‐Man, R. (2009) · ChemMedChem · doi:10.1002/cmdc.200900032 · Cited by 25 · see citing works

The role of GLP ‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

Dar, S., Tahrani, A. A., & Piya, M. K. (2015) · Practical Diabetes · doi:10.1002/pdi.1978 · Cited by 23 · see citing works

Synthetic Approaches toward Vitamin B12 Conjugates

Wierzba, A. J., Hassan, S., & Gryko, D. (2018) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.201800579 · Cited by 21 · see citing works

Expanded Use of Exenatide in the Management of Type 2 Diabetes

John, L. E., Kane, M. P., Busch, R. S., & Hamilton, R. A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.1.59 · Cited by 20 · see citing works

Enhanced Peptide Stability Against Protease Digestion Induced by Intrinsic Factor Binding of a Vitamin B12 Conjugate of Exendin-4

Bonaccorso, R. L., Chepurny, O. G., Becker‐Pauly, C., Holz, G. G., & Doyle, R. P. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00390 · Cited by 18 · see citing works

Chronic Exendin-4 Treatment Prevents the Development of Cancer Cachexia Symptoms in Male Rats Bearing the Yoshida Sarcoma

Honors, M. A., & Kinzig, K. P. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0163-9 · Cited by 17 · see citing works

Comparison of Recombinant Human Haptocorrin Expressed in Human Embryonic Kidney Cells and Native Haptocorrin

Furger, E., Fedosov, S. N., Lildballe, D. L., Waibel, R., Schibli, R., Nexø, E., & Fischer, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037421 · Cited by 16 · see citing works

A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew)

Chan, S. W., Lin, G., Yew, D. T. W., & Rudd, J. A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.06.036 · Cited by 15 · see citing works

Cobalamin binding proteins (haptocorrin and transcobalamin) in human cerebrospinal fluid

Hansen, M., Brynskov, J., Christensen, P. A., Krintel, J. J., & Gimsing, P. (1985) · Scandinavian Journal of Haematology · doi:10.1111/j.1600-0609.1985.tb02778.x · Cited by 14 · see citing works

Gastrointestinal safety across the albiglutide development programme

Leiter, L., Mallory, J. M., Wilson, T. H., & Reinhardt, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12679 · Cited by 13 · see citing works

Quantitation of intrinsic factor [letter]

Herbert, V., & Herzlich, B. C. (1983) · Blood · doi:10.1182/blood.v61.4.819.819 · Cited by 1 · see citing works

Safety of Semaglutide

Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332 · see citing works

GIP receptor agonism attenuates GLP-1 receptor agonist induced nausea and emesis in preclinical models

Borner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202 · see citing works

Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment

Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154 · see citing works

The therapeutic potential of GLP‐1 receptor biased agonism

Jones, B. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15497 · Cited by 99 · see citing works

Enteroendocrine cell regulation of the gut-brain axis

Barton, J. R., Londregan, A., Alexander, T. D., Entezari, A. A., Covarrubias, M., & Waldman, S. A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1272955 · Cited by 90 · see citing works

Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?

Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & Jonghe, B. C. D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 48 · see citing works

Ghrelin and Glucagon-Like Peptide-1: A Gut-Brain Axis Battle for Food Reward

Décarie-Spain, L., & Kanoski, S. E. (2021) · Nutrients · doi:10.3390/nu13030977 · Cited by 45 · see citing works

Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation

Xie, H., Yepuri, N., Meng, Q., Dhawan, R., Leech, C. A., Chepurny, O., Holz, G. G., & Cooney, R. (2020) · Reviews in Endocrine & Metabolic Disorders · doi:10.1007/s11154-020-09584-3 · Cited by 37 · see citing works

GLP-1R Signaling and Functional Molecules in Incretin Therapy

Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44 · see citing works

GIP receptor agonism blocks chemotherapy-induced nausea and vomiting

Borner, T., Reiner, B. C., Crist, R. C., Furst, C. D., Doebley, S. A., Halas, J. G., Ai, M., Samms, R. J., Jonghe, B. C. D., & Hayes, M. R. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101743 · Cited by 40 · see citing works

GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance

Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35 · see citing works

GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment

Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 29 · see citing works

Peptide GLP-1 receptor agonists: From injection to oral delivery strategies

Ke, Z., Ma, Q., Ye, X., Wang, Y., Jin, Y., Zhao, X., & Su, Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116471 · Cited by 24 · see citing works

The antiemetic actions of GIP receptor agonism

Borner, T., Jonghe, B. C. D., & Hayes, M. R. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2023 · Cited by 23 · see citing works

An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database

Butucă, A., Dobrea, C. M., Arseniu, A. M., Frum, A., Chiş, A. A., Rus, L. L., Ghibu, S., Juncan, A. M., Muntean, A. C., Lazăr, A. E., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12051124 · Cited by 23 · see citing works

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article

Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 19 · see citing works

Hypophagia induced by salmon calcitonin, but not by amylin, is partially driven by malaise and is mediated by CGRP neurons

Boccia, L., Borner, T., Ghidewon, M. Y., Kulka, P., Piffaretti, C., Doebley, S. A., Jonghe, B. C. D., Grill, H. J., Lutz, T. A., & Foll, C. L. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101444 · Cited by 17 · see citing works

Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models

Borner, T., Pataro, A. M., Doebley, S. A., Furst, C. D., White, A. D., Gao, S. X., Chow, A., Sanchez-Navarro, M. J., Ghidewon, M. Y., Halas, J. G., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu1589 · Cited by 15 · see citing works

Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases

Lyons, S. A., & Beaudry, J. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad153 · Cited by 15 · see citing works

Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 15 · see citing works

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP

Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 15 · see citing works

Peripherally restricted oxytocin is sufficient to reduce food intake and motivation, while CNS entry is required for locomotor and taste avoidance effects

Asker, M., Krieger, J., Liles, A., Tinsley, I. C., Borner, T., Marić, I., Doebley, S. A., Furst, C. D., Börchers, S., Longo, F., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14937 · Cited by 14 · see citing works

Regulation of Energy and Glucose Homeostasis by the Nucleus of the Solitary Tract and the Area Postrema

Bruce, K., Garrido, A. N., Zhang, S., & Lam, T. K. T. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2025 · Cited by 13 · see citing works

The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs

Douros, J. D., Mowery, S. A., & Knerr, P. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113812 · Cited by 12 · see citing works

Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4

Tinsley, I. C., Borner, T., Swanson, M. L., Chepurny, O. G., Doebley, S. A., Kamat, V., Sweet, I. R., Holz, G. G., Hayes, M. R., Jonghe, B. C. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00185 · Cited by 11 · see citing works

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland

Hoffmann, K., Michalak, M., & Paczkowska, A. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s531697 · Cited by 9 · see citing works

GLP ‐ 1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models

Baumer-Harrison, C., Aldaghma, D., White, A. D., Applebey, S. V., Pataro, A. M., Mohiby, A. Z., Alonso, B., Xiao, A. G., O’Farrell, L. S., Qian, Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70427 · Cited by 6 · see citing works

A novel gene therapy platform for the treatment of type 2 diabetes and obesity

Lourie, J., Goraltchouk, A., Hollander, J. M., BERGER, N. J. A., Rosen, H. G., Fujishiro, A. A., Luppino, F., Seregin, A., Rhym, L. H., & Zou, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102739 · Cited by 4 · see citing works

Corrination mitigates peptide aggregation as exemplified for Glucagon

Liles, A., Cham, N., Opp, M. L., Tinsley, I. C., Chepurny, O. G., Holz, G. G., & Doyle, R. P. (2023) · Peptides · doi:10.1016/j.peptides.2023.171134 · Cited by 4 · see citing works

GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist Induced Nausea and Emesis in Preclinical Models

Borner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina‐Fernandez, J., Dogra, M., Doebley, S. A., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · doi:10.2337/figshare.15125112.v1 · Cited by 4 · see citing works

Gastrointestinal adverse events of semaglutide in patients with overweight or obesity

Tariq, M. A., Amin, H. M., Shurjeel, Q., Gang, A., & Mohiuddin, A. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.08.015 · Cited by 3 · see citing works

A deep learning-based system for automatic detection of emesis with high accuracy in Suncus murinus

Lu, Z., Qiao, Y., Huang, X., Cui, D., Liu, J. Y. H., Ngan, M. P., Liu, L., Huang, Z. L., Li, Z., Yang, L., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07479-0 · Cited by 2 · see citing works

Evaluating Linker Architecture in RNA-Detecting Riboglow Probes and Effects on Fluorescence Turn-On

Shafik, L. K., Francis, G. M., Chitu, G., Hanson, J., Lis, S., Cunningham, K., Tatarian, B., Dyke, A. R. V., & Braselmann, E. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.5c00917 · Cited by 1 · see citing works

Corrin Ring Modification in Peptide Drug Development – a Brief History of “Corrination”

Cham, N., & Doyle, R. P. (2025) · ChemMedChem · doi:10.1002/cmdc.202500129 · Cited by 1 · see citing works

Advancements and challenges in the management of obesity using pharmacotherapy (Review)

Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1 · see citing works

GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist Induced Nausea and Emesis in Preclinical Models

Borner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina‐Fernandez, J., Dogra, M., Doebley, S. A., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · doi:10.2337/figshare.15125112

The chemistry of the cobalt corrinoids ― Recent advances and emerging themes. Part 3. Cobalamins and health

Marques, H. M. (2026) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2026.113395

Rapport 26-08. Les agonistes des récepteurs aux incrétines dans le traitement de l’obésité : entre efficacité clinique, éthique et économie de la santé

Malbert, C., Delarue, J., & Guéant, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.07.004

A Dicyanocobinamide Conjugate of the GLP-1R Agonist Exendin-4 Improves Glucose Homeostasis in Tumor-Bearing Rats without Exacerbating Anorexia and Weight Loss

Cham, N., Pataro, A. M., Liles, A., Choi, G. K., Fischer, S. L., Ramadan, S. A., Gao, S. X., Doebley, S. A., Chepurny, O. G., Holz, G. G., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00590

A second‐generation glucagon‐like peptide‐1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models

Borner, T., Shaulson, E. D., Tinsley, I. C., Stein, L. M., Horn, C. C., Hayes, M. R., Doyle, R. P., & Jonghe, B. C. D. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14089 · Cited by 23 · see citing works

Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in Suncus murinus (house musk shrew)

Chan, S. W., Lin, G., Yew, D. T. W., Yeung, C. K., & Rudd, J. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.01.013 · Cited by 34 · see citing works

GLP ‐ 1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models

Baumer-Harrison, C., Aldaghma, D., White, A. D., Applebey, S. V., Pataro, A. M., Mohiby, A. Z., Alonso, B., Xiao, A. G., O’Farrell, L. S., Qian, Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70427 · Cited by 6 · see citing works

A vitamin B12 conjugate of exendin‐4 improves glucose tolerance without associated nausea or hypophagia in rodents

Mietlicki‐Baase, E. G., Liberini, C. G., Workinger, J. L., Bonaccorso, R. L., Borner, T., Reiner, D. J., Koch‐Laskowski, K., McGrath, L. E., Lhamo, R., Stein, L. M., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13222 · Cited by 36 · see citing works

Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?

Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & Jonghe, B. C. D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 48 · see citing works